2nd Quarter - Report

RYAN MACKINNON VASAPOLI AND BERZOK, LLP for GENENTECH

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

Comparative Effectiveness and H.R. 1 American Recovery and Reinvestment Act of 2009.

LobbyistCovered position, as disclosed
MATTHEW BERZOK —
NICK KOLOVOS —
JEFF MACKINNON —
THOMAS RYAN —
JOSEPH V VASAPOLI —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1 (111th)

Pharmacy PHA

Issues regarding follow on biologics, HR 5629 Pathway for Biosimilar Act; S 1695 Biologics, Price Competition and Innovation Act of 2007, JR 1956 - provide for approval of similar biological products, HR 5629 - establish a pathway for the licensure of biosimilar biological products, HR 1038 - provide for licensing of comparable and interchangeable biological products.

LobbyistCovered position, as disclosed
MATTHEW BERZOK —
NICK KOLOVOS —
JEFF MACKINNON —
THOMAS RYAN —
JOSEPH V VASAPOLI —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1038 (111th), H.R. 5629 (111th)

Medical/Disease Research/Clinical Labs MED

Comparative Effectiveness and H.R. 1 American Recovery and Reinvestment Act of 2009

LobbyistCovered position, as disclosed
MATTHEW BERZOK —
NICK KOLOVOS —
JEFF MACKINNON —
THOMAS RYAN —
JOSEPH V VASAPOLI —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1 (111th)

Health Issues HCR

Monitor federal related to Medicare and other health care issues. Budget resolution FY2010, Pathway for Biosimilars Act (H.R. 1548). Health Care Reform Legislation. Pharmaceutical import safety legislation.

LobbyistCovered position, as disclosed
MATTHEW BERZOK —
NICK KOLOVOS —
JEFF MACKINNON —
THOMAS RYAN —
JOSEPH V VASAPOLI —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1548 (111th)

Medicare/Medicaid MMM

Comparative Effectiveness and H.R. 1 American Recovery and Reinvestment Act of 2009. Monitor federal related to Medicare and other health care issues. In addition, Patent Reform Act of 2009 (H.R. 1260/ S.515/ S.610). Budget resoluition FY2010, Pathway for Biosimilars Act (H.R. 1548). Health Care Reform Legislation. Pharmaceutical import safety legislation.

LobbyistCovered position, as disclosed
MATTHEW BERZOK —
NICK KOLOVOS —
JEFF MACKINNON —
THOMAS RYAN —
JOSEPH V VASAPOLI —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 610 (111th), H.R. 1260 (111th), H.R. 1548 (111th), H.R. 1 (111th), S. 515 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.